Nationwide Fund Advisors increased its stake in shares of Evolent Health Inc. (NYSE:EVH) by 474.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,119 shares of the company’s stock after buying an additional 48,010 shares during the period. Nationwide Fund Advisors owned approximately 0.10% of Evolent Health worth $1,431,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the stock. Blair William & Co. IL increased its stake in Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock valued at $6,558,000 after buying an additional 229,748 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in Evolent Health during the second quarter valued at approximately $1,565,000. Swiss National Bank increased its stake in Evolent Health by 90.2% in the second quarter. Swiss National Bank now owns 32,900 shares of the company’s stock valued at $632,000 after buying an additional 15,600 shares during the last quarter. Systematic Financial Management LP bought a new stake in Evolent Health during the second quarter valued at approximately $3,480,000. Finally, Schwab Charles Investment Management Inc. increased its stake in Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock valued at $822,000 after buying an additional 504 shares during the last quarter. 51.70% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Evolent Health Inc. (NYSE:EVH) traded down 7.14% on Tuesday, reaching $18.85. The company’s stock had a trading volume of 365,059 shares. The firm has a 50 day moving average of $21.03 and a 200 day moving average of $20.98. Evolent Health Inc. has a 12 month low of $8.14 and a 12 month high of $26.84. The firm’s market cap is $1.28 billion.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The firm earned $60.20 million during the quarter, compared to the consensus estimate of $58.35 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. The company’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) earnings per share. Analysts anticipate that Evolent Health Inc. will post ($0.57) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The original version of this report can be viewed at http://www.dailypolitical.com/2016/11/29/evolent-health-inc-evh-position-raised-by-nationwide-fund-advisors.html.

Several equities research analysts have recently commented on EVH shares. Zacks Investment Research raised Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Tuesday, October 11th. William Blair restated an “outperform” rating on shares of Evolent Health in a research note on Friday, September 30th. Canaccord Genuity set a $30.00 price target on Evolent Health and gave the company a “buy” rating in a research note on Wednesday, September 28th. JPMorgan Chase & Co. began coverage on Evolent Health in a research note on Friday, October 28th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Leerink Swann set a $24.00 price target on Evolent Health and gave the company a “buy” rating in a research note on Monday, November 21st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Evolent Health has an average rating of “Buy” and a consensus target price of $27.83.

In related news, Director Michael D’amato bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The shares were bought at an average price of $17.18 per share, with a total value of $171,800.00. Following the completion of the transaction, the director now directly owns 18,183 shares in the company, valued at $312,383.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Board Co Advisory sold 1,936,529 shares of Evolent Health stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $22.50, for a total value of $43,571,902.50. Following the transaction, the insider now directly owns 4,445,879 shares in the company, valued at approximately $100,032,277.50. The disclosure for this sale can be found here. Corporate insiders own 8.85% of the company’s stock.

About Evolent Health

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health Inc. (NYSE:EVH).

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.